20.500.12556/DiRROS-29240 Janus kinase inhibitors – a new effective treatment option for refractory isolated non-infectious ocular inflammatory disorders The Janus kinase (JAK) pathway regulates inflammatory responses, with dysregulation implicated in various autoimmune disorders, including non-infectious orbital or ocular inflammation. While corticosteroids are commonly used, their long-term use is limited by side effects. Janus kinase inhibitors (JAK-i) present an emerging therapeutic option. This study systematically reviewed the effectiveness and safety of JAK-i in managing isolated non-infectious ocular inflammation. A comprehensive literature review utilizing MEDLINE/PubMed, Cochrane and Web of Science search identified studies reporting isolated non-infectious ocular inflammation cases treated with JAK-i up to May 2025. Search terms combined JAK-i keywords with ocular inflammation terms. Among 21 isolated non-infectious ocular inflammation cases treated with JAK-i, tofacitinib was predominant. Most patients received JAK-i after disease-modifying antirheumatic drug therapy, with additional corticosteroid usage. Ocular inflammation was successfully controlled in 21 out of 21 patients, with one case of herpetic keratitis necessitating additoinal systemic virostatics. JAK-i show promise as an effective option for refractory isolated non-infectious ocular inflammation. However, further research is warranted with longer follow-up periods. Safety concerns underline the importance of personalized risk-benefit assessments in JAK-i therapy. While limitations exist, this review supports the potential of JAK-i use in managing isolated non-infectious ocular inflammation. Putanja Janus kinase (JAK) regulira upalne odgovore, uz deregulaciju uključenu u raznim autoimunim poremećajima uključujući nezaraznu upalu orbite ili oka. Iako se kortikosteroidi redovito primjenjuju u takvim slučajevima, njihova dugotrajna uporaba ograničena je nuspojavama, a tu se pojavljuju inhibitori Janus kinaze (JAK-i) kao mogućnost liječenja. U ovom istraživanju sustavno je obrađena učinkovitost i sigurnost JAK-i u liječenju izolirane nezarazne očne upale. U sveobuhvatnom pregledu literature pretragom izvora MEDLINE/PubMed, Cochrane i Web of Science identificirane su studije koje izvještavaju o slučajevima izolirane nezarazne očne upale liječene pomoću JAK-i do svibnja 2025. godine. Pretražni pojmovi kombinirali su ključne riječi JAK-i s terminima očne upale. Taofacitinib je prevladavao među 21 slučajem izolirane nezarazne očne upale. Većina bolesnika primala je JAK-i nakon terapije antireumatskim lijekovima koji mijenjaju tijek bolesti, uz dodatnu primjenu kortikosteroida. Očna upala je uspješno kontrolirana u 21 od 21 bolesnika, pričem je jedan slučaj herpetskog keratitisa zahtijevao dodatne sistemske virostatike. JAK-i obećava kao učinkovita opcija za refraktornu izoliranu nezaraznu upalu oka. Međutim, potrebna su daljnja istraživanja s dužim vremenom praćenja. Pitanja sigurnosti naglašavaju važnost personalizirane procjene rizika i koristi liječenja pomoću JAK-i. Iako postoje ograničenja, ovaj pregled podupire potencijal primjene JAK-i u liječenju izolirane nezarazne očne upale. Janus kinase inhibitors non-infectious ocular inflammation uveitis zaviralci Janus kinaze neinfekcijsko vnetje očesa uveitis inhibitori Janus kinaze nezarazna očna upala uveitis true false true Angleški jezik Hrvaški jezik Neznano 2026-05-04 08:49:24 2026-05-04 08:49:25 2026-05-05 03:45:43 0000-00-00 00:00:00 2026 0 0 Nasl. z nasl. zaslona; Opis vira z dne 22. 4. 2026; str. 162-171 no. 1 Vol. 65 2026 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 617.7 1333-9451 10.20471/acc.2026.65.01.15 276084995 RAZ_Vidic_Krhlikar_Nina_2026.pdf RAZ_Vidic_Krhlikar_Nina_2026.pdf 1 87BA9325729198D08E6EADA26A27D158 2a3d478be789d8382a074a504218698abd658f147556a78a3018a40e8103174e c92c3dea-4786-11f1-969d-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=43748 https://hrcak.srce.hr/clanak/499246 0 ec228a35-4786-11f1-969d-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=43749 Univerzitetni klinični center Ljubljana 0 0 0